Cargando…
Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment
New tools are needed to match cancer patients with effective treatments. Patient-derived organoids offer a high-throughput platform to personalize treatments and discover novel therapies. Currently, methods to evaluate drug response in organoids are limited because they overlook cellular heterogenei...
Autores principales: | Sharick, Joe T., Walsh, Christine M., Sprackling, Carley M., Pasch, Cheri A., Pham, Dan L., Esbona, Karla, Choudhary, Alka, Garcia-Valera, Rebeca, Burkard, Mark E., McGregor, Stephanie M., Matkowskyj, Kristina A., Parikh, Alexander A., Meszoely, Ingrid M., Kelley, Mark C., Tsai, Susan, Deming, Dustin A., Skala, Melissa C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242740/ https://www.ncbi.nlm.nih.gov/pubmed/32500020 http://dx.doi.org/10.3389/fonc.2020.00553 |
Ejemplares similares
-
Autofluorescence Imaging of Treatment Response in Neuroendocrine Tumor Organoids
por: Gillette, Amani A., et al.
Publicado: (2021) -
Cellular Metabolic Heterogeneity In Vivo Is Recapitulated in Tumor Organoids()
por: Sharick, Joe T., et al.
Publicado: (2019) -
Impact of baseline culture conditions of cancer organoids when determining therapeutic response and tumor heterogeneity
por: DeStefanis, Rebecca A., et al.
Publicado: (2022) -
Patient-derived cancer organoid tracking with wide-field one-photon redox imaging to assess treatment response
por: Gil, Daniel A., et al.
Publicado: (2021) -
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K
por: Yueh, Alexander E., et al.
Publicado: (2016)